PROCEPT BioRobotics Corporation — Blitz Index 44 (C)
PROCEPT BioRobotics scores 44 — a surgical-robotics company growing +19% with 858 installed systems and a 66.3% gross margin, held back by decelerating growth, a thin moat, and a lawsuit over its handpiece revenue.
Last re-scored: November 11, 2026.
Confidence: High · Category: frontier
Score breakdown
| Section | Score | Detail |
|---|---|---|
| A · Speed | 17 / 25 | Revenue growth decelerating hard — FY2024 +64.8% → FY2025 +37.2% → 9M 2026 +19.1% — though procedures keep rising (+56% in FY2025) and the installed base grew to 858 systems |
| B · Moat | 28 / 60 | A razor/blade model with clinical evidence (~250 peer-reviewed papers, WATER trial) and a $30B TAM — but no network effect (B1 4) and distribution that costs ~74% of revenue in SG&A |
| C · Creative destruction | 8 / 15 | Aquablation displacing TURP, the historic standard, with superior safety in the randomised WATER trial — but at ~10.8% procedure share the displacement is still early, and the handpiece price is rising, not falling |
| D · BlitzFailing | −9 | Revenue quality is the drag (D2 −4): handpieces +7% vs procedures +69% after the Q4 2025 incentive unwind, plus a securities class action on the same handpiece claims (D4 −3) — 6 points short of a FLAG |
Think we scored it wrong? Score it yourself →
Radar axes (0–100): Moat 46.7 · Speed 68.0 · Creative 53.3.
Watch item
Gates: G1 ✓ (confirmed — razor/blade repeat purchase with consumables ~65% of revenue at +21% YoY, and procedures +56% in FY2025) · G2 ✓ (confirmed — a ~$30B US TAM against a $3.52B bar, ~8.5×, with even the narrowest vendor estimate at ~3.5×). 21 points below the 65-point threshold — the installed-base engine is real, but growth is decelerating and the moat is thin. Watch the securities lawsuit, handpiece ASP and discounting, and whether growth holds at ~19%.
Strengths
- Razor/blade repeat purchase proven: handpieces and consumables $53.86M in Q3 2026 (+21% YoY), ~65% of revenue, handpiece units ≈ 106% of procedures
- Installed base compounding: 315 systems (Q4 2023) → 858 (Q3 2026), with 31.8% penetration of target hospitals and FY2026 procedure guidance of 54,000–56,000
- Clinical evidence as the moat's foundation: ~250 peer-reviewed papers and the WATER trial's superior safety vs TURP — the only randomised FDA pivotal trial against TURP
- Margins expanding: gross margin 52.2% → 66.3% (Q3 2026) and the operating loss rate improving from −80.2% to −27.9%
- A large market with a second curve: a ~$30B US TAM (8.5× the G2 bar) plus the WATER IV prostate-cancer trial (FDA IDE + Breakthrough Device, data targeted H1 2027)
Concerns
- Growth decelerating: +64.8% → +37.2% → ~+19%, with Q4 2025 at +11.9%; FY2026 guidance of +27–33% is no return to the old pace
- Never profitable: cumulative deficit −$726.6M, operating loss rate −27.9% in Q3 2026, and 9M operating cash burn of −$66.4M — a ~2.5-year simple runway
- Thin moat: no network effect (B1 4) and distribution that costs ~74% of revenue in SG&A (B2 6) — moat converts to only 46.7
- Revenue quality in question: handpieces +7% vs procedures +69% in Q4 2025 after the incentive unwind — the same gap the securities class action alleges
- Two lawsuits, both early: a securities class action (July 2026) and a shareholder derivative suit on the same handpiece and discounting claims, with no provision booked
Research notes
Thesis: the installed-base engine, questioned revenue
PROCEPT BioRobotics Corporation enters the BlitzLab record with a first scoring of 44 out of 100, grade C, built from Speed 17 out of 25, Moat 28 out of 60, Creative Destruction 8 out of 15, and deductions of 9. The total sits 21 points below the 65-point line, and the shape of the score is the story: on the radar conversion used by the model, Speed converts to 68.0, Creative Destruction to 53.3, and Moat to only 46.7. This is a surgical-robotics company — trailing-twelve-month revenue of $352.3 million — whose Aquablation system displaces TURP in benign prostatic hyperplasia surgery on a razor/blade model: one disposable handpiece per procedure, consumables at ~65% of revenue, and an installed base that grew from 315 systems to 858 in under three years. Both gates pass on a confirmed basis. The fourth quarter of 2026 has not been reported at T, and its reporting date is unconfirmed — it is not a company-confirmed date and must not be presented as one — and no outcome is anticipated here. That is the balance of the record at T: an installed-base engine that is real, growth that is decelerating, and a revenue-quality question that a lawsuit now tests.
The gates: both pass — repeat purchase proven, market ample
Gate 1, two pieces of product-market-fit evidence for a growth company, passes on a confirmed basis. Repeat purchase is the razor/blade model itself: handpieces and consumables were $53.86 million in the third quarter of 2026, up 21% year on year and ~65% of quarterly revenue, with handpiece units at ~106% of procedures. Organic growth is the procedure count: 16,500 in fiscal 2023, 27,700 in fiscal 2024, 43,300 in fiscal 2025, and 13,400 in the third quarter of 2026 (+22% year on year). Gate 2, a ten-year market ceiling at least ten times current revenue, also passes on a confirmed basis: the company's US TAM of ~$30 billion is ~8.5 times the bar of ~$3.52 billion, and even the narrowest independent vendor estimate ($12.4 billion) clears the bar ~3.5 times. The deductions are the other half of the gate story: 9 points — dilution-funded growth at minus 2, revenue quality at minus 4, and two lawsuits at minus 3 — so the company is not flagged, but 6 points from the flag line. If the lawsuit is dismissed or the handpiece-procedure gap closes, the deductions ease; if growth slips below 10% or the litigation hardens, they deepen.
More Frontier companies
Other Frontier names on the Blitz Index, highest score first: Rocket Lab (64/B), Tesla (62/B), Illumina (61/B).
Next earnings
Not announced.
Coverage
PROCEPT BioRobotics Corporation · Q3 2026 reported Nov 4, 2026 · Score 44 · Grade C
Embed this score
Copy the HTML below to show this score on your site. The badge links back to this page and updates automatically when the score changes.
Preview:
BlitzLab scores businesses against a scholar’s standard — not investment advice. No price targets, no buy/sell recommendations. Figures are from SEC filings (XBRL) as labeled in the source scorecard.